Scher HI Graf RP Schreiber

[13] Scher HI, Graf RP, Schreiber NA, et al. Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 2017;71:874–82. [14] Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circu-lating tumor 13(S)-HODE as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016;2:1441–9.
[15] Todenhofer T, Azad A, Stewart C, et al. AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate. J Urol 2017;197:135–42.
[16] Zhu Y, Sharp A, Anderson CM, et al. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. Eur Urol 2018;73:727–35.
[17] Scher HI, Graf RP, Schreiber NA, et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant pros-tate cancer. JAMA Oncol 2018;4:1179–86.
[18] Welti J, Rodrigues DN, Sharp A, et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol 2016;70:599–608.
[19] Sharp A, Coleman I, Yuan W, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest 2019;129:192–208.
[20] Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 2017;35:2149–56.
[21] Tagawa ST, Antonarakis ES, Gjyrezi A, et al. Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY. Clin Cancer Res 2019;25:1880–8.
[23] Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897–904.
[24] de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302–9. [25] Seed G, Yuan W, Mateo J, et al. Gene copy number estimation from targeted next-generation sequencing of prostate cancer biopsies: analytic validation and clinical qualification. Clin Cancer Res 2017;23:6070–7.
[27] Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015;1:582–91.
[28] Danila DC, Samoila A, Patel C, et al. Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant pros-tate cancer patients. Cancer J 2016;22:315–20.
[29] Chalfin HJ, Glavaris SA, Malihi PD, et al. Prostate cancer dissemi-nated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell detection platforms. J Urol 2018;199:1494–501.
Please cite this article in press as: Sharp A, et al. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.04.006 ARTICLE IN PRESS
Urologic Oncology: Seminars and Original Investigations 000 (2019) 1−9
Original article
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer
Jason Zhu, MDa, Matthew Tucker, MDa, Daniele Marin, MDb, Rajan T. Gupta, MDb,c, Patrick Healy, MSd, Michael Humeniuk, MDe, Casey Jarvis, MSN, FNP-C, RNa, Tian Zhang, MD, MHSa,c, Megan McNamara, MDa,c, Daniel J. George, MDa,c, Yuan Wu, PhDd, Stacey Lisi, PharmD, BCOPc, Andrew J. Armstrong, MD, ScM, FACPa,c,f,*
a Department of Medicine, School of Medicine, Duke University, Durham, NC b Department of Radiology, Duke University, Durham, NC
c Duke Cancer Institute Center for Prostate and Urologic Cancer, Durham, NC d Department of Biostatistics, Duke University, Durham, NC e Gibbs Cancer Center, Spartanburg Regional Healthcare System, Spartanburg, SC